|
PT2391638T
(pt)
*
|
2009-02-02 |
2018-10-19 |
Glaxosmithkline Biologicals Sa |
Sequências de aminoácidos e ácidos nucleicos de adenovírus símio, vetores contendo as mesmas, e as suas utilizações
|
|
JP5980117B2
(ja)
|
2009-11-09 |
2016-08-31 |
ジェンヴェック，インコーポレーテッド |
サルアデノウイルスベクターの増殖方法
|
|
WO2011130627A2
(en)
|
2010-04-16 |
2011-10-20 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Chimpanzee adenoviral vector-based filovirus vaccines
|
|
EP3075860A1
(en)
*
|
2010-11-23 |
2016-10-05 |
The Trustees of the University of Pennsylvania |
Subfamily e simian adenovirus a1295 and uses thereof
|
|
WO2012089231A1
(en)
|
2010-12-30 |
2012-07-05 |
Okairòs Ag |
Paramyxovirus vaccines
|
|
TWI623618B
(zh)
|
2011-07-12 |
2018-05-11 |
傳斯堅公司 |
Ｈｂｖ聚合酶突變體
|
|
WO2013045658A1
(en)
|
2011-09-29 |
2013-04-04 |
Transgene Sa |
Immunotherapy composition and regimen for treating hepatitis c virus infection
|
|
WO2013045668A2
(en)
|
2011-09-29 |
2013-04-04 |
Transgene Sa |
Immunotherapy composition and regimen for treating hepatitis c virus infection
|
|
JP6757120B2
(ja)
|
2011-10-05 |
2020-09-16 |
ジェンヴェック エルエルシー |
アーフェンアデノウイルス（ゴリラ）又はアデノウイルスベクター、及び使用方法
|
|
CN103987726B
(zh)
|
2011-10-05 |
2017-10-03 |
金维克有限公司 |
猴(大猩猩)腺病毒或腺病毒载体及其使用方法
|
|
IN2014DN03005A
(enExample)
|
2011-10-05 |
2015-05-08 |
Genvec Inc |
|
|
WO2013074501A1
(en)
|
2011-11-14 |
2013-05-23 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
|
CA2864956C
(en)
|
2012-03-12 |
2021-11-09 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
|
NZ701324A
(en)
|
2012-05-04 |
2016-09-30 |
Pfizer |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
|
JP6293738B2
(ja)
*
|
2012-05-18 |
2018-03-14 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
亜科ｅサルアデノウイルスａ１３０２、ａ１３２０、ａ１３３１及びａ１３３７ならびにそれらの使用
|
|
US9676824B2
(en)
|
2012-05-29 |
2017-06-13 |
Genvec, Inc. |
Herpes simplex virus vaccine
|
|
WO2014005643A1
(en)
|
2012-07-05 |
2014-01-09 |
Okairos Ag |
Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
|
|
PL2869841T3
(pl)
|
2012-07-05 |
2022-01-24 |
Glaxosmithkline Biologicals Sa |
Nowe schematy prime-boost wykorzystujące polipeptydy immunogenne kodowane przez polinukleotydy
|
|
CN105051198A
(zh)
|
2012-11-16 |
2015-11-11 |
貝丝以色列女执事医疗中心 |
重组腺病毒及其用途
|
|
CA2903582C
(en)
|
2013-03-14 |
2021-06-08 |
Salk Institute For Biological Studies |
Oncolytic adenovirus compositions
|
|
WO2014139587A1
(en)
|
2013-03-15 |
2014-09-18 |
Okairòs Ag |
Improved poxviral vaccines
|
|
SG11201508567XA
(en)
|
2013-04-25 |
2015-11-27 |
Crucell Holland Bv |
Stabilized soluble prefusion rsv f polypeptides
|
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
|
CN106659777A
(zh)
|
2014-06-13 |
2017-05-10 |
葛兰素史密丝克莱恩生物有限公司 |
免疫原性组合产品
|
|
JP2017527564A
(ja)
|
2014-09-03 |
2017-09-21 |
バヴァリアン ノルディック エー／エス |
免疫応答の増進を目的とする方法及び組成物
|
|
CN107454848B
(zh)
|
2014-09-03 |
2021-06-22 |
巴法里安诺迪克有限公司 |
用于诱导针对丝状病毒感染的保护性免疫的方法和组合物
|
|
WO2017025782A1
(en)
|
2014-09-17 |
2017-02-16 |
Glaxosmithkline Biologicals Sa |
Improved poxviral vaccines
|
|
CA2961024A1
(en)
|
2014-09-26 |
2016-03-31 |
Beth Israel Deaconess Medical Center, Inc. |
Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
|
|
WO2016128542A1
(en)
|
2015-02-13 |
2016-08-18 |
Transgene Sa |
Immunotherapeutic vaccine and antibody combination therapy
|
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
|
CN107466324B
(zh)
|
2015-04-14 |
2022-01-14 |
扬森疫苗与预防公司 |
具有双向启动子的表达两种转基因的重组腺病毒
|
|
DK3294326T3
(da)
|
2015-05-15 |
2021-05-31 |
Curevac Ag |
Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion
|
|
EA038402B9
(ru)
|
2015-06-12 |
2021-09-22 |
Глаксосмитклайн Байолоджикалс Са |
Аденовирусные полинуклеотиды и полипептиды
|
|
BE1024824B1
(fr)
*
|
2015-06-12 |
2018-07-13 |
Glaxosmithkline Biologicals Sa |
Polynucleotides et polypeptides d'adenovirus
|
|
GB201514772D0
(en)
*
|
2015-08-19 |
2015-09-30 |
Glaxosmithkline Biolog Sa |
Adenovirus polynucleotides and polypeptides
|
|
EA039065B1
(ru)
|
2015-07-07 |
2021-11-29 |
Янссен Вэксинс Энд Превеншн Б.В. |
Вакцина против rsv
|
|
US10457708B2
(en)
|
2015-07-07 |
2019-10-29 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion RSV F polypeptides
|
|
GB201513176D0
(en)
*
|
2015-07-27 |
2015-09-09 |
Glaxosmithkline Biolog Sa |
Novel methods for inducing an immune response
|
|
CA3008542C
(en)
|
2015-12-15 |
2020-06-02 |
Janssen Vaccines & Prevention B.V. |
Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
|
|
SG11201805621SA
(en)
|
2016-01-19 |
2018-08-30 |
Pfizer |
Cancer vaccines
|
|
WO2017147265A1
(en)
|
2016-02-23 |
2017-08-31 |
Salk Institute For Biological Studies |
High throughput assay for measuring adenovirus replication kinetics
|
|
JP7015551B2
(ja)
|
2016-02-23 |
2022-02-15 |
ソーク インスティテュート フォー バイオロジカル スタディーズ |
ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
|
|
CN117534735A
(zh)
|
2016-03-31 |
2024-02-09 |
欧洲分子生物学实验室 |
腺病毒外壳蛋白衍生递送载体
|
|
EP3808374A1
(en)
|
2016-04-05 |
2021-04-21 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion rsv f proteins for use in the prophylaxis of rsv infection
|
|
CN109069612A
(zh)
|
2016-04-05 |
2018-12-21 |
扬森疫苗与预防公司 |
针对rsv的疫苗
|
|
EP3452081A1
(en)
|
2016-05-04 |
2019-03-13 |
Transgene SA |
Combination therapy with cpg tlr9 ligand
|
|
BR112018072865A2
(pt)
|
2016-05-12 |
2019-04-30 |
Janssen Vaccines & Prevention B.V. |
promotor bidirecional potente e equilibrado
|
|
PE20190110A1
(es)
|
2016-05-30 |
2019-01-15 |
Janssen Vaccines And Prevention B V |
Proteinas f de prefusion del vrs estabilizadas
|
|
EP3472327B1
(en)
|
2016-06-20 |
2020-08-19 |
Janssen Vaccines & Prevention B.V. |
Potent and balanced bidirectional promoter
|
|
GB2549809C
(en)
|
2016-06-23 |
2022-11-30 |
Univ Oxford Innovation Ltd |
Vector
|
|
WO2018011768A1
(en)
|
2016-07-15 |
2018-01-18 |
Janssen Vaccines And Prevention B.V. |
Methods and compositions for inducing protective immunity against a marburg virus infection
|
|
US10925955B2
(en)
|
2016-07-15 |
2021-02-23 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against a Marburg virus infection
|
|
CA3034124A1
(en)
|
2016-08-23 |
2018-03-01 |
Glaxosmithkline Biologicals Sa |
Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
|
|
WO2018060288A1
(en)
|
2016-09-29 |
2018-04-05 |
Glaxosmithkline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
US20190328869A1
(en)
|
2016-10-10 |
2019-10-31 |
Transgene Sa |
Immunotherapeutic product and mdsc modulator combination therapy
|
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
|
ES2959811T3
(es)
*
|
2016-12-09 |
2024-02-28 |
Glaxosmithkline Biologicals Sa |
Construcciones de adenovirus de chimpancé con antígenos de Lyssavirus
|
|
CA3045892A1
(en)
|
2016-12-12 |
2018-06-21 |
Salk Institute For Biological Studies |
Tumor-targeting synthetic adenoviruses and uses thereof
|
|
GB201701239D0
(en)
*
|
2017-01-25 |
2017-03-08 |
Glaxosmithkline Biologicals Sa |
Novel formulation
|
|
CN110268061B
(zh)
|
2017-02-09 |
2024-07-16 |
扬森疫苗与预防公司 |
用于表达异源基因的有效的短启动子
|
|
US11173204B2
(en)
|
2017-04-06 |
2021-11-16 |
Janssen Vaccines & Prevention B.V. |
MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
|
|
CA3062591A1
(en)
|
2017-05-08 |
2018-11-15 |
Gritstone Oncology, Inc. |
Alphavirus neoantigen vectors
|
|
CA3062614A1
(en)
*
|
2017-05-10 |
2018-11-15 |
University Of Utah Research Foundation |
Compositions and methods of use of arc capsids
|
|
CA3061278A1
(en)
|
2017-05-17 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against rsv infection
|
|
WO2018210871A1
(en)
|
2017-05-17 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against rsv infection
|
|
EP3638302B1
(en)
|
2017-06-15 |
2024-03-13 |
Janssen Vaccines & Prevention B.V. |
Poxvirus vectors encoding hiv antigens, and methods of use thereof
|
|
JP7274222B2
(ja)
*
|
2017-07-05 |
2023-05-16 |
ノイスコム アーゲー |
非ヒト大型類人猿アデノウイルスの核酸配列及びアミノ酸配列、それを含有するベクター、並びにその使用
|
|
SG11202000197PA
(en)
|
2017-07-11 |
2020-02-27 |
Pfizer |
Immunogenic compositions comprising cea muc1 and tert
|
|
MX2020000414A
(es)
|
2017-07-12 |
2020-09-28 |
Nouscom Ag |
Composicion de vacuna de neoantigeno para el tratamiento del cancer.
|
|
WO2019016756A1
(en)
|
2017-07-21 |
2019-01-24 |
Glaxosmithkline Biologicals Sa |
ANTIGEN CONSTRUCTS OF CHIKUNGUNYA VIRUSES
|
|
BR112020001052A2
(pt)
|
2017-07-28 |
2020-09-08 |
Janssen Vaccines & Prevention B.V. |
métodos e composições para imunizações heterólogas com reprna
|
|
BR112020004143A2
(pt)
|
2017-09-15 |
2020-09-01 |
Janssen Vaccines & Prevention B.V. |
método para a indução segura de imunidade contra vírus sincicial respiratório (rsv)
|
|
WO2019076892A1
(en)
|
2017-10-16 |
2019-04-25 |
Glaxosmithkline Biologicals Sa |
ENHANCED PROMOTER
|
|
US11859199B2
(en)
|
2017-10-16 |
2024-01-02 |
Glaxosmithkline Biologicals Sa |
Adenoviral vectors with two expression cassettes encoding RSV antigenic proteins or fragments thereof
|
|
CN111479926A
(zh)
|
2017-10-16 |
2020-07-31 |
葛兰素史密丝克莱恩生物有限公司 |
具有两个表达盒的猿猴腺病毒载体
|
|
SG11202003058UA
(en)
|
2017-10-16 |
2020-04-29 |
Glaxosmithkline Biologicals Sa |
Replication competent adenoviral vectors
|
|
EP3704256A1
(en)
|
2017-10-31 |
2020-09-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus vectors and uses thereof
|
|
AU2018359492B2
(en)
*
|
2017-10-31 |
2023-12-14 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
|
MX2020004487A
(es)
|
2017-10-31 |
2020-08-13 |
Janssen Vaccines & Prevention Bv |
Adenovirus y usos de estos.
|
|
US11236361B2
(en)
*
|
2017-10-31 |
2022-02-01 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
|
AU2018358019B2
(en)
|
2017-11-03 |
2023-05-11 |
Nouscom Ag |
Vaccine T cell enhancer
|
|
EP3713599A1
(en)
|
2017-11-20 |
2020-09-30 |
Janssen Pharmaceuticals, Inc. |
Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
|
|
WO2019118480A1
(en)
*
|
2017-12-11 |
2019-06-20 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant adenoviruses and uses thereof
|
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
|
MX2020006471A
(es)
|
2017-12-19 |
2020-09-22 |
Janssen Sciences Ireland Unlimited Co |
Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv).
|
|
BR112020012361A2
(pt)
|
2017-12-20 |
2020-11-24 |
Glaxosmithkline Biologicals S.A. |
constructos de antígeno do vírus epstein-barr
|
|
BR112020019942A2
(pt)
|
2018-04-09 |
2021-01-26 |
Salk Institute For Biological Studies |
composições de adenovírus oncolítico com propriedades de replicação aprimoradas
|
|
CN112638936A
(zh)
*
|
2018-06-12 |
2021-04-09 |
葛兰素史密丝克莱恩生物有限公司 |
腺病毒多核苷酸和多肽
|
|
EP3581201A1
(en)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 proteins and uses thereof
|
|
EP3587581A1
(en)
|
2018-06-26 |
2020-01-01 |
GlaxoSmithKline Biologicals S.A. |
Formulations for simian adenoviral vectors having enhanced storage stability
|
|
EP3810277A1
(en)
|
2018-07-20 |
2021-04-28 |
Janssen Vaccines & Prevention B.V. |
Recombinant adenoviral vector expressing zika antigen with improved productivity
|
|
GB201812647D0
(en)
*
|
2018-08-03 |
2018-09-19 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Viral vectors and methods for the prevention or treatment of cancer
|
|
SG11202101735PA
(en)
|
2018-10-19 |
2021-03-30 |
Nouscom Ag |
Teleost invariant chain cancer vaccine
|
|
PH12021550974A1
(en)
|
2018-11-13 |
2022-05-02 |
Janssen Vaccines & Prevention Bv |
Stablized pre-fusion rsv f proteins
|
|
EP3881324A1
(en)
|
2018-11-15 |
2021-09-22 |
Nouscom AG |
Selection of cancer mutations for generation of a personalized cancer vaccine
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
US20220339281A1
(en)
|
2019-03-05 |
2022-10-27 |
GalxoSmithKline Biologicals SA |
Hepatitis b immunisation regimen and compositions
|
|
US12329793B2
(en)
*
|
2019-03-20 |
2025-06-17 |
National University Corporation Hokkaido University |
Modified adenovirus and medicine comprising same
|
|
MX2021014525A
(es)
*
|
2019-05-30 |
2022-03-17 |
Gritstone Bio Inc |
Adenovirus modificados.
|
|
EP4125973A4
(en)
*
|
2019-11-04 |
2024-03-13 |
Gritstone bio, Inc. |
Neoantigen vaccine therapy
|
|
EP4061405A1
(en)
|
2019-11-18 |
2022-09-28 |
Janssen Biotech, Inc. |
Vaccines based on mutant calr and jak2 and their uses
|
|
CN113088530A
(zh)
*
|
2020-01-08 |
2021-07-09 |
怡道生物科技(苏州)有限公司 |
一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法
|
|
CN116096732A
(zh)
|
2020-01-31 |
2023-05-09 |
贝斯以色列护理医疗中心有限公司 |
用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
WO2021209897A1
(en)
|
2020-04-13 |
2021-10-21 |
Janssen Biotech, Inc. |
Psma and steap1 vaccines and their uses
|
|
KR20230009445A
(ko)
|
2020-05-11 |
2023-01-17 |
얀센 파마슈티칼즈, 인코포레이티드 |
안정화된 코로나바이러스 스파이크 단백질 융합 단백질
|
|
US20230233661A1
(en)
|
2020-06-29 |
2023-07-27 |
Janssen Vaccines & Prevention B.V. |
Vaccine combination against repiratory syncytial virus infection
|
|
PH12022553417A1
(en)
|
2020-07-06 |
2024-04-22 |
Janssen Pharmaceuticals Inc |
Stabilized corona virus spike protein fusion proteins
|
|
EP4175721A1
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
US20230035403A1
(en)
|
2020-07-06 |
2023-02-02 |
Janssen Biotech, Inc. |
Method For Determining Responsiveness To Prostate Cancer Treatment
|
|
EP4175664A2
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
PH12023550030A1
(en)
|
2020-07-08 |
2024-03-11 |
Janssen Sciences Ireland Unlimited Co |
Rna replicon vaccines against hbv
|
|
TW202217002A
(zh)
|
2020-07-13 |
2022-05-01 |
法商傳斯堅公司 |
免疫抑制之治療
|
|
CA3187258A1
(en)
*
|
2020-08-06 |
2022-02-10 |
Karin Jooss |
Multiepitope vaccine cassettes
|
|
US12275766B2
(en)
|
2020-12-23 |
2025-04-15 |
Janssen Biotech, Inc. |
Neoantigen peptide mimics
|
|
WO2022175479A1
(en)
|
2021-02-19 |
2022-08-25 |
Janssen Vaccines & Prevention B.V. |
Vaccine combinations against respiratory syncytial virus strain a and b infections
|
|
WO2022175477A1
(en)
|
2021-02-19 |
2022-08-25 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion rsv fb antigens
|
|
US20240197859A1
(en)
|
2021-04-01 |
2024-06-20 |
Janssen Vaccines & Prevention B.V. |
Stabilized Pre-Fusion PIV3 F Proteins
|
|
WO2022218997A1
(en)
|
2021-04-12 |
2022-10-20 |
Centre National De La Recherche Scientifique (Cnrs) |
Novel universal vaccine presenting system
|
|
AU2022299252A1
(en)
|
2021-06-21 |
2023-11-23 |
Nouscom Ag |
Vaccine composition comprising encoded adjuvant
|
|
WO2023020939A1
(en)
|
2021-08-17 |
2023-02-23 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
WO2023026182A1
(en)
|
2021-08-24 |
2023-03-02 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
WO2023047348A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceuticals, Inc. |
Stabilized corona virus spike protein fusion proteins
|
|
WO2023047349A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceuticals, Inc. |
Stabilized coronavirus spike protein fusion proteins
|
|
WO2023111725A1
(en)
|
2021-12-14 |
2023-06-22 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
EP4448802A1
(en)
|
2021-12-16 |
2024-10-23 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion hmpv fusion proteins
|
|
WO2023198815A1
(en)
|
2022-04-14 |
2023-10-19 |
Janssen Vaccines & Prevention B.V. |
Sequential administration of adenoviruses
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
EP4590690A1
(en)
|
2022-09-23 |
2025-07-30 |
Janssen Vaccines & Prevention B.V. |
Pre-fusion human piv1 f proteins
|
|
WO2024061759A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Stabilized coronavirus s proteins
|
|
CR20250116A
(es)
|
2022-10-06 |
2025-05-05 |
Msd Int Business Gmbh |
Proteína f de piv3 de prefusión estabilizadas
|
|
WO2025158316A1
(en)
|
2024-01-26 |
2025-07-31 |
Janssen Biotech, Inc. |
Ovarian neoantigens and use thereof
|